학술논문
IL-22BP controls the progression of liver metastasis in colorectal cancer
Document Type
article
Author
Anastasios D. Giannou; Jan Kempski; Tao Zhang; Jöran Lücke; Ahmad Mustafa Shiri; Dimitra E. Zazara; Ioannis Belios; Andres Machicote; Philipp Seeger; Theodora Agalioti; Joseph Tintelnot; Adrian Sagebiel; Miriam Tomczak; Lennart Bauditz; Tanja Bedke; Lorenz Kocheise; Baris Mercanoglu; Mohammad Fard-Aghaie; Emmanouil Giorgakis; Panagis M. Lykoudis; Anastasia Pikouli; Julia-Kristin Grass; Ramez Wahib; Jan Bardenhagen; Benjamin Brunswig; Asmus Heumann; Tarik Ghadban; Anna Duprée; Michael Tachezy; Nathaniel Melling; Petra C. Arck; Pablo Stringa; Maria Virginia Gentilini; Gabriel E. Gondolesi; Ryosuke Nakano; Angus W. Thomson; Daniel Perez; Jun Li; Oliver Mann; Jakob R. Izbicki; Nicola Gagliani; Ioannis C. Maroulis; Samuel Huber
Source
Frontiers in Oncology, Vol 13 (2023)
Subject
Language
English
ISSN
2234-943X
Abstract
BackgroundThe immune system plays a pivotal role in cancer progression. Interleukin 22 binding protein (IL-22BP), a natural antagonist of the cytokine interleukin 22 (IL-22) has been shown to control the progression of colorectal cancer (CRC). However, the role of IL-22BP in the process of metastasis formation remains unknown.MethodsWe used two different murine in vivo metastasis models using the MC38 and LLC cancer cell lines and studied lung and liver metastasis formation after intracaecal or intrasplenic injection of cancer cells. Furthermore, IL22BP expression was measured in a clinical cohort of CRC patients and correlated with metastatic tumor stages.ResultsOur data indicate that low levels of IL-22BP are associated with advanced (metastatic) tumor stages in colorectal cancer. Using two different murine in vivo models we show that IL-22BP indeed controls the progression of liver but not lung metastasis in mice.ConclusionsWe here demonstrate a crucial role of IL-22BP in controlling metastasis progression. Thus, IL-22 might represent a future therapeutic target against the progression of metastatic CRC.